Treatment patterns, survival, and hospitalization in adult patients with acute lymphoblastic leukemia: an observational cohort study using SEER Medicare data

References

• Jabbour E, O'Brien S, Konopleva M, et al. New insights into the pathophysiology and therapy of adult acute lymphoblastic leukemia. Cancer. 2015;121:2517–2528.
   PubMed Web of Science ®Google Scholar
• Howlader N, Noone AM, Krapcho M, et al., editors. SEER cancer statistics review, 1975–2013. Bethesda (MD): National Cancer Institute.
   Google Scholar
• Jabbour EJ, Faderl S, Kantarjian HM. Adult acute lymphoblastic leukemia. Mayo Clin Proc. 2005;80:1517–1527.
   PubMed Web of Science ®Google Scholar
• Alvarnas JC, Brown PA, Aoun P, et al. Acute lymphoblastic leukemia. J Natl Compr Cancer Netw. 2012;10:858–914.
   PubMed Web of Science ®Google Scholar
• Fedorov VD, Upadhyay VA, Fathi AT. The approach to acute lymphoblastic leukemia in older patients: conventional treatment and emerging therapies. Curr Hematol Malig Rep. 2016;11:165–174.
   PubMed Web of Science ®Google Scholar
• Paul S, Kantarjian H, Jabbour EJ. Adult acute lymphoblastic leukemia. Mayo Clin Proc. 2016;91:1645–1666.
   PubMed Web of Science ®Google Scholar
• Larson RA, Dodge RK, Burns CP. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. Blood. 1995;85:2025–2037.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Thomas D, O’Brien S, et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer. 2004;101:2788–2801.
   PubMed Web of Science ®Google Scholar
• Thomas DA, O'Brien S, Faderl S, et al. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. JCO. 2010;28:3880–3889.
   PubMed Web of Science ®Google Scholar
• Ravandi F, O’Brien S, Thomas D, et al. First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. Blood. 2010;116:2070–2077.
   PubMed Web of Science ®Google Scholar
• Thomas DA, Faderl S, Cortes J, et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood. 2004;103:4396–4407.
   PubMed Web of Science ®Google Scholar
• Mizuta S, Matsuo K, Yagasaki F, et al. Pre-transplant imatinib-based therapy improves the outcome of allogeneic hematopoietic stem cell transplantation for BCR-ABL-positive acute lymphoblastic leukemia. Leukemia. 2011;25:41–47.
   PubMed Web of Science ®Google Scholar
• Yanada M, Takeuchi J, Sugiura I, et al. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. JCO. 2006;24:460–466.
   PubMed Web of Science ®Google Scholar
• Vignetti M, Fazi P, Cimino G, et al. Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell’Adulto (GIMEMA) LAL0201-B protocol. Blood. 2007;109:3676–3678.
   PubMed Web of Science ®Google Scholar
• Foa R, Vitale A, Vignetti M, et al. Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2011;118:6521–6528.
   PubMed Web of Science ®Google Scholar
• Linker C, Damon L, Ries C, et al. Intensified and shortened cyclical chemotherapy for adult acute lymphoblastic leukemia. JCO. 2002;20:2464–2471.
   PubMed Web of Science ®Google Scholar
• Rowe JM, Buck G, Burnett AK, et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood. 2005;106:3760–3767.
   PubMed Web of Science ®Google Scholar
• Griffiths R, Gleeson M, Reyes C, et al. Survival in elderly follicular lymphoma patients who receive frontline chemo-immunotherapy. Am J Hematol. 2010;85:963–967.
   PubMed Web of Science ®Google Scholar
• Danese MD, Griffiths RI, Gleeson M, et al. An observational study of outcomes after initial infused therapy in Medicare patients diagnosed with chronic lymphocytic leukemia. Blood. 2011;117:3505–3513.
   PubMed Web of Science ®Google Scholar
• Lindquist KJ, Danese MD, Mikhael J, et al. Health care utilization and mortality among elderly patients with myelodysplastic syndromes. Ann Oncol. 2011;22:1181–1188.
   PubMed Web of Science ®Google Scholar
• Griffiths R, Mikhael J, Gleeson M, et al. Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphoma. Blood. 2011;118:4808–4816.
   PubMed Web of Science ®Google Scholar
• Griffiths RI, Gleeson ML, Mikhael J, et al. Comparative effectiveness and cost of adding rituximab to first-line chemotherapy for elderly patients diagnosed with diffuse large B-cell lymphoma. Cancer. 2012;118:6079–6088.
   PubMed Web of Science ®Google Scholar
• Murthy GSG, Venkitachalam R, Mehta P. Trends in survival outcomes of B-lineage acute lymphoblastic leukemia in elderly patients: analysis of Surveillance, Epidemiology, and End Results database. Leuk Lymph. 2015;56:2296–2300.
   PubMed Web of Science ®Google Scholar
• Abel GA. The real world: CLL. Blood. 2011;117:3481–3482.
   PubMed Web of Science ®Google Scholar
• Warren JL, Klabunde CN, Schrag D, et al. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002;40:IV-3–IV-18.
   Web of Science ®Google Scholar
• National Cancer Institute. Surveillance, epidemiology, and end results program. List of SEER registries; [cited 2017 Feb 12]. Available from: http://seer.cancer.gov/registries/list.html
   Google Scholar
• National Cancer Institute. Overview of the SEER program; [cited 2017 Feb 12]. Available from: https://healthcaredelivery.cancer.gov/seermedicare/overview/linked.html
   Google Scholar
• World Health Organization. International classification of diseases for oncology, 3rd edition (ICD-O-3); [cited 2017 Feb 12]. Available from: http://www.who.int/classifications/icd/adaptations/oncology/en/
   Google Scholar
• National Cancer Institute. Surveillance, epidemiology, and end results program. Site recode ICD-O-3 (1/27/2003) definition; [cited 2017 Feb 12]. Available from: https://seer.cancer.gov/siterecode/icdo3_d01272003/
   Google Scholar
• Fritz A, Ries L, editors. SEER program code manual. 3rd ed. Bethesda: Cancer Statistics Branch, Surveillance Program, Div of Cancer Control and Pop Sciences, National Cancer Institute, National Institutes of Health, Public Health Service, U.S. Dept of Health and Human Services; 1998.
   Google Scholar
• Pulte D, Redaniel MT, Jansen L, et al. Recent trends in survival of adult patients with acute leukemia: overall improvements, but persistent and partly increasing disparity in survival of patients from minority groups. Haematologica. 2013;98:222–229.
   PubMed Web of Science ®Google Scholar
• Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649–655.
   PubMed Web of Science ®Google Scholar
• Davidoff AJ, Tang M, Seal B, et al. Chemotherapy and survival benefit in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol. 2010;28:2191–2197.
   PubMed Web of Science ®Google Scholar
• Griffiths RI, Gleeson ML, Mikhael J, et al. Impact on medical cost, cumulative survival, and cost-effectiveness of adding rituximab to first-line chemotherapy for follicular lymphoma (FL) in elderly patients: an observational cohort study based on SEER-Medicare. J Cancer Epidemiol. 2012;2012:1.
   Google Scholar
• Klabunde CN, Potosky AL, Legler JM, et al. Development of a comorbidity index using physician claims data. J Clin Epidemiol. 2000;53:1258–1267.
   PubMed Web of Science ®Google Scholar
• Klabunde CN, Legler JM, Warren JL, et al. A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients. Ann Epidemiol. 2007;17:584–590.
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–383.
   PubMedGoogle Scholar
• Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613–619.
   PubMed Web of Science ®Google Scholar
• Romano PS, Roos LL, Luft HS, et al. A comparison of administrative versus clinical data: coronary artery bypass surgery as an example. Ischemic Heart Disease Patient Outcomes Research Team. J Clin Epidemiol. 1994;47:249–260.
   PubMed Web of Science ®Google Scholar
• Practice Management Information Corporation. ICD-9-CM. 6th ed. Los Angeles: Practice Management Information Corporation; 2009.
   Google Scholar
• Practice Management Information Corporation. HCPCS. Los Angeles: Practice Management Information Corporation; 2009.
   Google Scholar
• Warren JL, Harlan LC, Fahey A, et al. Utility of the SEER-Medicare data to identify chemotherapy use. Med Care. 2002;40:IV-55–IV-61.
   Web of Science ®Google Scholar
• National Cancer Institute. Procedure codes for SEER Medicare analyses; [cited 2017 Feb 12]. Available from: http://healthservices.cancer.gov/seermedicare/considerations/procedure_codes.html
   Google Scholar
• Hernán MA, Robins JM. Estimating causal effects from epidemiological data. J Epidemiol Community Health. 2006;60:578–586.
   PubMed Web of Science ®Google Scholar